31
Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:August 14, 2023Active, not recruiting
Refractory Multiple Myeloma: 1501 Clinical Trials, Page 4 of 151
Hide Studies Not Open or Pending
32
INCB053914 and Pomalidomide With Dexamethasone for Relapsed and/or Refractory Multiple Myeloma
Condition(s):Refractory Multiple Myeloma; Relapse Multiple MyelomaLast Updated:August 19, 2020Withdrawn
33
Evaluate the Safety, Tolerability, and Efficacy of ICP-490 in Patients With Relapsed and/or Refractory Multiple Myeloma
Condition(s):Relapsed and/or Refractory Multiple MyelomaLast Updated:April 18, 2023Recruiting
34
Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple Myeloma
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:March 23, 2023Terminated
35
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:August 7, 2023Recruiting
36
A Study of Real-life Current Standards of Care in Patients With Relapsed and/or Refractory Multiple Myeloma Who Received at Least 3 Prior Lines of Therapy Including Proteasome Inhibitor (PI), Immunomodulatory Drug (IMID), and Cluster of Differentiation 38 (CD38) Monoclonal Antibody Treatment
Condition(s):Multiple MyelomaLast Updated:December 21, 2022Completed
37
A Single-center Exploratory Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of a BCMA-targeted Universal LCAR-BCX Cells in Patients With Relapsed/Refractory Multiple Myeloma
Condition(s):Relapsed/Refractory Multiple MyelomaLast Updated:November 2, 2021Active, not recruiting
38
This is an Open-label, Single Arm Study to Evaluate the Safety and Tolerability of Treatment With CT0591CP in Patients With Relapsed and/or Refractory Multiple Myeloma.
Condition(s):Relapsed and/or Refractory Multiple MyelomaLast Updated:April 12, 2023Recruiting
39
Safety Study of Lenalidomide/Dexamethasone to Treat Patients With Relapsed or Refractory Multiple Myeloma
Condition(s):Multiple MyelomaLast Updated:June 30, 2022Completed
40
INCB001158 Combined With Subcutaneous (SC) Daratumumab, Compared to Daratumumab SC, in Relapsed or Refractory Multiple Myeloma
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:March 20, 2023Terminated